1. Home
  2. MQ vs MLYS Comparison

MQ vs MLYS Comparison

Compare MQ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marqeta Inc.

MQ

Marqeta Inc.

HOLD

Current Price

$4.34

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$29.25

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MQ
MLYS
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.2B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
MQ
MLYS
Price
$4.34
$29.25
Analyst Decision
Hold
Strong Buy
Analyst Count
10
7
Target Price
$5.36
$48.67
AVG Volume (30 Days)
2.7M
1.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
$624,884,000.00
N/A
Revenue This Year
$16.89
N/A
Revenue Next Year
$16.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.25
N/A
52 Week Low
$3.70
$12.59
52 Week High
$7.04
$47.65

Technical Indicators

Market Signals
Indicator
MQ
MLYS
Relative Strength Index (RSI) 56.36 57.16
Support Level $3.84 $26.85
Resistance Level $4.50 $31.19
Average True Range (ATR) 0.13 1.65
MACD 0.01 -0.15
Stochastic Oscillator 62.38 64.08

Price Performance

Historical Comparison
MQ
MLYS

About MQ Marqeta Inc.

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: